Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 8/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.53 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | RARB | P10826 | 1/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.53 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59197 | 0.84 | PTGS2 (0.74) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL464579 | 0.79 | HPGD (0.48) | PTGS2PTGS1CXCR1CXCR2ESR1 | |
| SCHEMBL4651605 | 0.78 | PTGS2 (0.65) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL6551674 | 0.78 | PTGS2 (0.65) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL917093 | 0.78 | PTGS2 (0.87) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL13749706 | 0.77 | HSD17B10 (0.36) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL22501317 | 0.77 | PTGS2 (0.50) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL12062811 | 0.76 | KMT2A (0.40) | PTGS2PTGS1LMNATSHRALDH1A1 | |
| SCHEMBL892055 | 0.76 | PTGS2 (0.63) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL3093415 | 0.76 | PTGS2 (0.63) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3231793-A1 | DIHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2017-10-18 | — | — | EP | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8084484-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090156590-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156590-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions | TRPV1, OPRL1, TRPV2 | PTGS2 181/4885PTGS1 137/4885AKR1C3 1349/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | PTGS2 347/4885PTGS1 188/4885AKR1C3 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.